Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TICDEs: Xintong Oral Liquid for Ischemic Cardiovascular Disease with Diabetes
NCT07088523Phase 4Not yet recruiting
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hexintong in myocardial infarction (MI) (2 arms), sponsored by Guangzhou University of Chinese Medicine. Primary endpoint: Major Adverse Cardiovascular and Cerebrovascular Events at 90 days. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
hexintong
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT07088523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07088523.